Literature DB >> 11111821

Efficacy of different low-density lipoprotein apheresis methods.

K G Parhofer1, H C Geiss, P Schwandt.   

Abstract

Low-density lipoprotein (LDL) apheresis is a treatment option in patients with coronary heart disease and drug resistant hypercholesterolemia. Various apheresis systems based on different elimination concepts are currently in use. We compared the efficacy of 4 different apheresis systems concerning the elimination of lipoproteins. The study included 7 patients treated by heparin extracorporeal LDL precipitation (HELP), 10 patients treated by immunoadsorption, 8 patients treated by dextran-sulfate adsorption, and 4 patients treated by cascade filtration. Ten subsequent aphereses were evaluated in patients undergoing regular apheresis for more than 6 months. Total cholesterol decreased by approximately 50% with all 4 systems. LDL cholesterol (LDL-C) (64-67%) and lipoprotein a [Lp(a)] (61-64%) were decreased more effectively by HELP, immunoadsorption, and dextran-sulfate apheresis than by the less specific cascade filtration system [LDL-C reduction 56%, Lp(a) reduction 53%]. Triglyceride concentrations were reduced by 40% (dextran-sulfate) to 49% (cascade filtration) and high-density lipoproteins (HDL) by 9% (dextran-sulfate) to 25% (cascade filtration). On the basis of plasma volume treated, HELP was the most efficient system (LDL-C reduction 25.0%/L plasma), followed by dextran-sulfate (21.0%/L plasma), cascade (19.4%/L plasma), and immunoadsorption (17.0%/L plasma). However, a maximal amount of 3 L plasma can be processed with HELP due to concomitant fibrinogen reduction while there is no such limitation with immunoadsorption. Therefore, the decision of which system should be used in a given patient must be individualized taking the pre-apheresis LDL concentration, concomitant pharmacotherapy, and fibrinogen concentration into account.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11111821     DOI: 10.1046/j.1526-0968.2000.004005382.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  6 in total

1.  LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection.

Authors:  Alexina Orsoni; Samir Saheb; Johannes H M Levels; Geesje Dallinga-Thie; Marielle Atassi; Randa Bittar; Paul Robillard; Eric Bruckert; Anatol Kontush; Alain Carrié; M John Chapman
Journal:  J Lipid Res       Date:  2011-09-26       Impact factor: 5.922

Review 2.  Lipoprotein apheresis to treat elevated lipoprotein (a).

Authors:  Elisa Waldmann; Klaus G Parhofer
Journal:  J Lipid Res       Date:  2016-02-17       Impact factor: 5.922

3.  Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia.

Authors:  Alexina Orsoni; Elise F Villard; Eric Bruckert; Paul Robillard; Alain Carrie; Dominique Bonnefont-Rousselot; M John Chapman; Geesje M Dallinga-Thie; Wilfried Le Goff; Maryse Guerin
Journal:  J Lipid Res       Date:  2012-02-15       Impact factor: 5.922

Review 4.  [Lipoprotein apheresis : State of the art and case report of the longest HELP treatment worldwide].

Authors:  Adrienn Tünnemann-Tarr; Julius Ludwig Katzmann; Joachim Thiery; Ulrich Laufs
Journal:  Herz       Date:  2022-04-22       Impact factor: 1.443

5.  Successful treatment of homozygous familial hypercholesterolemia using cascade filtration plasmapheresis.

Authors:  Fatih Kardaş; Aysun Cetin; Musa Solmaz; Rüksan Büyükoğlan; Leylagül Kaynar; Mustafa Kendirci; Bülent Eser; Ali Unal
Journal:  Turk J Haematol       Date:  2011-04-01       Impact factor: 1.831

6.  Lipoprotein turnover and possible remnant accumulation in preeclampsia: insights from the Freiburg Preeclampsia H.E.L.P.-apheresis study.

Authors:  Christine Contini; Martin Jansen; Brigitte König; Filiz Markfeld-Erol; Mirjam Kunze; Stefan Zschiedrich; Ulrich Massing; Irmgard Merfort; Heinrich Prömpeler; Ulrich Pecks; Karl Winkler; Gerhard Pütz
Journal:  Lipids Health Dis       Date:  2018-03-14       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.